/ 2 items

#OVID↓

OVID/ 12/22/2025 · 10:36 AM

Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings

Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.

OVID/ 10/03/2025 · 7:31 AM

Ovid Therapeutics Secures Major Funding & Announces Positive Drug Trial Results

Ovid Therapeutics secured up to $175 million in financing to fund its clinical pipeline into 2028. The company also reported positive Phase 1 results for OV329, a next-generation epilepsy drug candidate.